Skip to main content

Table 2 Specific EZH2 inhibitors in lymphoid malignancies

From: EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications

Inhibitor(s) Malignancies Authors
GSK126 EZH2-mutant and wild-type GC-DLBCL, FL, ABC-DLBCL, T-ALL, MCL, ATLL, CTCL, MM Xu L., et al. [122]; Lue JK., et al. [123]; Adamik J., et al. [124]; Zeng D., et al. [125]; Ott HM., et al. [126]; McCabe MT., et al. [35]
GSK343 MM Ezponda T., et al. [127]
EI1 EZH2-mutant GC-DLBCL Qi W., et al. [128]
EPZ-6438 EZH2-mutant and wild-type GC-DLBCL, MM Herviou L., et al. [129]; Dimopoulos K., et al. [130]; Brach D., et al. [131]; Knutson SK., et al. [132]
EPZ005687 EZH2-mutant and wild-type GC-DLBCL Knutson SK., et al. [133]
EPZ011989 EZH2-mutant GC-DLBCL Campbell JE., et al. [134]
EBI-2511 EZH2-mutant GC-DLBCL Lu B., et al. [135]
ZLD10A EZH2-mutant GC-DLBCL Song X., et al. [136]
DCE_42/254 EZH2-mutant and wild-type GC-DLBCL Wu Y., et al. [137]
CPI-1205 EZH2-mutant GC-DLBCL Vaswani RG., et al. [138]
Tetramethyl-piperidinyl Benzamides EZH2-mutant GC-DLBCL Nasveschuk CG., et al. [139]
  1. Abbreviations: GC-DLBCL germinal center diffuse large B cell lymphoma, ABC-DLBCL activated B cell-like diffuse large B cell lymphoma, FL follicular lymphoma, T-ALL T cell acute lymphoblastic leukemia, CTCL cutaneous T cell lymphoma, MCL mantel cell lymphoma, ATLL adult T cell leukemia/lymphoma, MM multiple myeloma